CARPRIEVE 100 MG TABLETS FOR DOGS.
Țară: Irlanda
Limbă: engleză
Sursă: HPRA (Health Products Regulatory Authority)
Caracteristicilor produsului
(SPC)
04-05-2024
Unele documente pentru acest produs nu sunt disponibile în prezent, puteți trimite o solicitare la serviciul nostru pentru clienți și vă vom anunța de îndată ce vom putea să le obținem.
Trimite cerere.
Trimite cerere.
Ingredient activ:
CARPROFEN
Disponibil de la:
Norbrook Laboratories Limited
Codul ATC:
QM01AE91
INN (nume internaţional):
CARPROFEN
Dozare:
100 Milligram
Forma farmaceutică:
Tablets
Tip de prescriptie medicala:
POM
Grupul Terapeutică:
Canine
Zonă Terapeutică:
Carprofen
Indicații terapeutice:
N.S.A.I.D
Statutul autorizaţiei:
Authorised
Data de autorizare:
2010-01-08
Caracteristicilor produsului
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprieve 100 mg Tablets for Dogs.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE INGREDIENTS:
Carprofen
100 mg
EXCIPIENTS:
Tartrazine (E102)
1.2 mg
For the full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablet.
A yellow circular tablet of 8 mm diameter, embossed “100” on one side and a single breakline on the other side.
The tablets can be divided into halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
In the dog:
Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow
up to parenteral analgesia in the management of post operative pain.
4.3 CONTRAINDICATIONS
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in puppies less than 4 months of age.
Do not use in animals with known hypersensitivity to the active substance or to any of the excipients.”
Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal
ulceration or bleeding, or where there is evidence of a blood dyscrasia.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5.
HEALTH PRODUCTS REGULATORY AUTHORITY
________________________________________________________________________________________________________________________
_Date Printed 04/07/2014_
_CRN 7015268_
_page number: 1_
4.5 SPECIAL PRECAUTIONS FOR USE
i.
Special precautions for use in animals
Use in aged dogs may involve additional risk.
If such a use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory con
Citiți documentul complet
